The archive's 19 chemo/radiation studies are presented on the homepage as 'scientific studies confirming what Dr. Diaa proposed'; the harm-only study selection implies that the harms of chemotherapy and radiotherapy outweigh their benefits.
Original statement
دراسات علمية تؤكد ما طرحه د. ضياء العوضي
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
The archive's 19 chemo/radiation studies are presented on the homepage as 'scientific studies confirming what Dr. Diaa proposed'; the harm-only study selection implies that the harms of chemotherapy and radiotherapy outweigh their benefits.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (homepage section heading above the study list)
- Origin
- https://eltayebat.com/
- Attribution uncertainty
- Written by archive operators; not attributed to Elawady.
- Population concerned
Cancer patients
- Geographic restriction by Elawady
none found
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Studies documenting late effects confirm Dr. Diaa's position (which, in his videos, is to avoid chemotherapy and radiotherapy).
2. What is demonstrably correct?
The late effects are real and correctly reported in most cases (C-CHM-01 to C-CHM-06). The archive narrative itself states that chemotherapy and radiotherapy 'have saved millions of lives' and that its text 'is not a call to refuse treatment' - this is fair and should be acknowledged.
3. What is wrong or exaggerated?
The bibliography quantifies only harms. Several of the archive's own studies report benefits that are not mentioned: trastuzumab halved recurrence and reduced deaths by a third (A-CHM-05); tamoxifen's net benefit 'greatly outweighs' its risk (A-CHM-08); most second cancers are not due to radiotherapy (A-CHM-07); testicular cancer has 95% 10-year survival (A-CHM-14); late mortality halved with modified treatment (A-CHM-11). Independent evidence: modern chemotherapy reduces breast-cancer mortality by about one-third with lower overall mortality (I-CHM-01); radiotherapy halves recurrence (I-CHM-02); alternative-only treatment of curable cancers was associated with a 2.5-fold higher risk of death (I-CHM-03). The harm studies therefore do not 'confirm' a position against these treatments.
4. What remains unclear?
Whether readers interpret the page as a recommendation to refuse treatment is not known.
5. Which studies support it?
6. Which studies contradict it?
I-CHM-01, I-CHM-02, I-CHM-03, I-CHM-04, I-CHM-05, I-CHM-12, A-CHM-05, A-CHM-07, A-CHM-08, A-CHM-14.
7. What applies to Germany and Europe?
Same evidence base applies.
8. What is known about Egypt?
Same evidence base applies.
9. What practical conclusion is appropriate?
A fair presentation should list benefit evidence (absolute survival gains) next to late effects.
Assessment details
- Rationale for certainty of evidence
The archive's own narrative concedes the benefit, but the study list quantifies only harms; high-certainty randomised and registry evidence shows large survival benefits and higher mortality when treatment is replaced.
- Source quality
Archive editorial framing.
- Regional transferability
High.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
The archive's study list on chemotherapy and radiotherapy shows real side effects: heart damage, second cancers, hearing loss and others. The archive text also admits these treatments save lives. But the list contains no study that measures how many lives are saved, and the homepage calls these studies a confirmation of Dr. Diaa's views. Large trials show that chemotherapy and radiotherapy clearly reduce deaths in many cancers, and that people who replace them with alternatives die more often.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (10)
-
Chemotherapy after breast-cancer surgery reduces deaths by about a third
EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5Meta-analysisindependent cross-checkfull text checked★ key studyIn 123 trials with 100,000 women, modern regimens cut breast-cancer deaths by about one-third, and overall deaths fell too.
Benefit omitted
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare chemotherapy regimens and no chemotherapy.
- How was the study done?
IPD meta-analysis of RCTs.
- How many people, animals or samples were studied?
~100,000 women.
- What was actually found?
~1/3 lower breast-cancer mortality.
- How large was the observed effect?
RR 0.64-0.78 vs none.
- What do the results mean in everyday life?
For many women, chemotherapy substantially raises the chance of survival.
- What are the study's limitations?
Trials versus no chemotherapy are old (median start 1986); a small excess of non-breast-cancer deaths (e.g. heart, leukaemia) occurred; benefit is small when baseline risk is low.
- What does it say about Elawady's specific claim?
Contradicts claims that chemotherapy is useless.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit without risk assessment.
-
Radiotherapy after breast-conserving surgery halves recurrence
EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2Meta-analysisindependent cross-checkfull text checked★ key studyRecurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.
Benefit omitted
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Measure radiotherapy benefit.
- How was the study done?
IPD meta-analysis.
- How many people, animals or samples were studied?
10,801 women.
- What was actually found?
Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.
- How large was the observed effect?
-15.7% recurrence; -3.8% death.
- What do the results mean in everyday life?
Radiotherapy markedly lowers the chance the cancer returns.
- What are the study's limitations?
Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Individual benefit size without risk factors.
-
Patients who used only alternative medicine for curable cancer died more often
Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145Cohort studyindependent cross-checkabstract only checked★ key studyRisk of death was 2.5 times higher overall and 5.7 times higher for breast cancer.
Refusing treatment costs lives
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare AM-only vs conventional treatment.
- How was the study done?
Matched registry cohort.
- How many people, animals or samples were studied?
840 matched patients.
- What was actually found?
HR 2.50 for death.
- How large was the observed effect?
HR 5.68 breast cancer.
- What do the results mean in everyday life?
Replacing cancer treatment with alternatives is dangerous.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusing therapy.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Effects of complementary approaches used alongside treatment.
-
Refusing standard cancer treatment, not complementary medicine itself, raised the risk of death
Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487Cohort studyindependent cross-checkabstract only checked★ key studyUsers of complementary medicine refused chemotherapy or radiotherapy far more often and had about twice the risk of death.
Benefit of adherence
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Study CM and survival.
- How was the study done?
Registry cohort.
- How many people, animals or samples were studied?
258 vs 1,032.
- What was actually found?
HR 2.08; explained by refusal.
- How large was the observed effect?
5-y OS 82.2% vs 86.6%.
- What do the results mean in everyday life?
Diet or other approaches alongside treatment are not the problem; replacing treatment is.
- What are the study's limitations?
Observational.
- What does it say about Elawady's specific claim?
Contradicts refusal advice.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Causal effect of any single CM.
-
About 9 in 10 children with leukaemia now survive
Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018Cohort studyindependent cross-checkabstract only checked★ key study5-year survival in childhood ALL rose to 90.4% by 2000-2005.
Benefit omitted
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Track ALL survival.
- How was the study done?
Trial cohort analysis.
- How many people, animals or samples were studied?
21,626.
- What was actually found?
83.7% -> 90.4%.
- How large was the observed effect?
+6.7 points.
- What do the results mean in everyday life?
Childhood leukaemia is usually curable with treatment.
- What are the study's limitations?
Trial patients.
- What does it say about Elawady's specific claim?
Benefit side.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Survival outside trials.
-
Cancer death rates in the USA keep falling
Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820Otherindependent cross-checkabstract only checkedMore than 4 million cancer deaths averted since 1991 thanks to less smoking, earlier detection and better treatment.
Treatment contributes to falling mortality
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Report cancer statistics.
- How was the study done?
Registry data.
- How many people, animals or samples were studied?
US population.
- What was actually found?
Declining mortality.
- How large was the observed effect?
>4 million deaths averted.
- What do the results mean in everyday life?
Prevention and treatment both work.
- What are the study's limitations?
Descriptive.
- What does it say about Elawady's specific claim?
Benefit context.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
Share due to treatment alone.
-
Adding trastuzumab to chemotherapy halved recurrence in HER2-positive breast cancer
Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122Randomised controlled trialcited by the Tayebat archiveabstract only checked★ key studyFewer recurrences and a third fewer deaths; serious heart problems in about 3-4 in 100 treated women.
Main result is benefit (HR 0.48; 33% fewer deaths)
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test trastuzumab added to chemotherapy.
- How was the study done?
Two RCTs analysed jointly.
- How many people, animals or samples were studied?
Operable HER2+ breast cancer.
- What was actually found?
HR 0.48 for events; 33% fewer deaths.
- How large was the observed effect?
+12% absolute DFS at 3 years.
- What do the results mean in everyday life?
Benefit clearly exceeds the cardiac risk for most patients; heart monitoring is needed.
- What are the study's limitations?
Interim analysis.
- What does it say about Elawady's specific claim?
Documents harm and much larger benefit.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That treatment should be avoided.
-
Only a small share of second cancers in adults is caused by radiotherapy
Berrington de Gonzalez A et al.. Lancet Oncol 2011 · PMID 21454129 · DOI 10.1016/S1470-2045(11)70061-4Cohort studycited by the Tayebat archivefull text checked★ key studyAbout 5 extra cancers per 1,000 treated patients within 15 years; 8% of second cancers in irradiated patients.
Authors conclude most second cancers are not due to RT
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Estimate radiotherapy-attributable second cancers.
- How was the study done?
SEER cohort.
- How many people, animals or samples were studied?
647,672 survivors.
- What was actually found?
8% attributable; 5/1000 by 15 years.
- How large was the observed effect?
RR 1.08-1.43.
- What do the results mean in everyday life?
The risk is real but small compared with the benefit of cure.
- What are the study's limitations?
No randomisation; no data on smoking, chemotherapy or doses; treatments before 2003.
- What does it say about Elawady's specific claim?
Limits the 'heavy price' framing.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Risk for an individual patient.
-
Tamoxifen raises the small risk of uterine cancer but prevents far more breast-cancer events
Fisher B et al.. J Natl Cancer Inst 1994 · PMID 8133536 · DOI 10.1093/jnci/86.7.527Randomised controlled trialcited by the Tayebat archiveabstract only checkedUterine cancer about 1.6 vs 0.2 per 1,000 women per year; 38% fewer recurrence-type events.
Authors: net benefit greatly outweighs risk
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Assess second cancers under tamoxifen.
- How was the study done?
RCT vs placebo.
- How many people, animals or samples were studied?
2,843 + 1,220.
- What was actually found?
RR 7.5 endometrial cancer; benefit outweighs.
- How large was the observed effect?
1.6 vs 0.2/1000/year.
- What do the results mean in everyday life?
Report abnormal bleeding during tamoxifen; continue therapy.
- What are the study's limitations?
Few events; data-integrity issue.
- What does it say about Elawady's specific claim?
Mixed.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
That tamoxifen is net harmful.
-
Testicular cancer survivors face late effects but almost all survive
Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832Narrative reviewcited by the Tayebat archivefull text checked10-year relative survival is 95%; heart disease and second cancers are the main serious late effects.
95% 10-year relative survival
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Review late effects.
- How was the study done?
Narrative review.
- What was actually found?
Multiple late effects.
- What do the results mean in everyday life?
Long-term check-ups and healthy lifestyle.
- What are the study's limitations?
Narrative review without systematic search or quality appraisal; much evidence from older treatment eras.
- What does it say about Elawady's specific claim?
Mixed.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Quantitative risks.
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
Late deaths among childhood-cancer survivors have fallen as treatment became gentler
Armstrong GT et al.. N Engl J Med 2016 · PMID 26761625 · DOI 10.1056/NEJMoa1510795Cohort studycited by the Tayebat archivefull text checked★ key study15-year death rate after surviving 5 years dropped from 12.4% to 6.0% between the 1970s and 1990s.
Oncology reduces late effects
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Track late mortality across eras.
- How was the study done?
Cohort, 34,033 survivors.
- How many people, animals or samples were studied?
34,033.
- What was actually found?
41% of late deaths health-related; mortality halved over time.
- How large was the observed effect?
12.4% -> 6.0%.
- What do the results mean in everyday life?
Late effects are real and being reduced.
- What are the study's limitations?
Observational era comparison; cannot measure improvements in medical care; treatment data imputed for 29%; shorter follow-up for the 1990s.
- What does it say about Elawady's specific claim?
Supports burden and shows progress.
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
That treatment should be avoided.
No study in this group is marked as key.
Regional context
Germany / EU
Same evidence base applies.
Egypt
Same evidence base applies.
What applies in my country?
General scientific assessment
Mostly false Documented side effects do not show that chemotherapy and radiotherapy do more harm than good; the benefit side is missing from the archive's evidence.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.. EBCTCG. Lancet 2012 · PMID 22152853 · DOI 10.1016/S0140-6736(11)61625-5
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
- Use of Alternative Medicine for Cancer and Its Impact on Survival.. Johnson SB et al.. J Natl Cancer Inst 2018 · PMID 28922780 · DOI 10.1093/jnci/djx145
- Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers.. Johnson SB et al.. JAMA Oncol 2018 · PMID 30027204 · DOI 10.1001/jamaoncol.2018.2487
- Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.. Hunger SP et al.. J Clin Oncol 2012 · PMID 22412151 · DOI 10.1200/JCO.2011.37.8018
- Cancer statistics, 2024.. Siegel RL et al.. CA Cancer J Clin 2024 · PMID 38230766 · DOI 10.3322/caac.21820
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.. Romond EH et al.. N Engl J Med 2005 · PMID 16236738 · DOI 10.1056/NEJMoa052122
- Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.. Berrington de Gonzalez A et al.. Lancet Oncol 2011 · PMID 21454129 · DOI 10.1016/S1470-2045(11)70061-4
- Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.. Fisher B et al.. J Natl Cancer Inst 1994 · PMID 8133536 · DOI 10.1093/jnci/86.7.527
- Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.. Fung C et al.. Adv Urol 2018 · PMID 29670654 · DOI 10.1155/2018/8671832
- Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.. Armstrong GT et al.. N Engl J Med 2016 · PMID 26761625 · DOI 10.1056/NEJMoa1510795